Literature DB >> 8257152

In vitro activity of penciclovir against clinical isolates of acyclovir-resistant and foscarnet-resistant herpes simplex virus.

S Safrin1, L Phan.   

Abstract

We tested 23 clinical isolates of acyclovir-susceptible, acyclovir-resistant, and foscarnet-resistant herpes simplex virus for susceptibility to penciclovir. Isolates showed cross-resistance to penciclovir and acyclovir, but penciclovir retained a relative activity against foscarnet-resistant isolates. Its clinical utility for the treatment of resistant herpes simplex virus infections remains to be studied.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8257152      PMCID： PMC192259          DOI： 10.1128/AAC.37.10.2241

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Drugs five years later: acyclovir.

Authors:  D I Dorsky; C S Crumpacker
Journal:  Ann Intern Med       Date:  1987-12       Impact factor: 25.391

2.  Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.

Authors:  C J Birch; G Tachedjian; R R Doherty; K Hayes; I D Gust
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

Review 3.  Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS.

Authors:  S Safrin
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

4.  Progressive esophagitis from acyclovir-resistant herpes simplex. Clinical roles for DNA polymerase mutants and viral heterogeneity?

Authors:  S L Sacks; R J Wanklin; D E Reece; K A Hicks; K L Tyler; D M Coen
Journal:  Ann Intern Med       Date:  1989-12-01       Impact factor: 25.391

5.  Mode of antiviral action of penciclovir in MRC-5 cells infected with herpes simplex virus type 1 (HSV-1), HSV-2, and varicella-zoster virus.

Authors:  D L Earnshaw; T H Bacon; S J Darlison; K Edmonds; R M Perkins; R A Vere Hodge
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Antiherpesvirus activity of 9-(4-hydroxy-3-hydroxy-methylbut-1-yl)guanine (BRL 39123) in cell culture.

Authors:  M R Boyd; T H Bacon; D Sutton; M Cole
Journal:  Antimicrob Agents Chemother       Date:  1987-08       Impact factor: 5.191

7.  In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.

Authors:  A Weinberg; B J Bate; H B Masters; S A Schneider; J C Clark; C G Wren; J A Allaman; M J Levin
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.

Authors:  C L Talarico; W C Phelps; K K Biron
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103
  8 in total
  4 in total

1.  Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2.

Authors:  R T Sarisky; T T Nguyen; K E Duffy; R J Wittrock; J J Leary
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 2.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

3.  Single-day famciclovir for the treatment of genital herpes: follow-up results of time to next recurrence and assessment of antiviral resistance.

Authors:  Neil Bodsworth; Kenneth Fife; William Koltun; Stephen Tyring; Mohammed Abudalu; Mark Prichard; Kamal Hamed
Journal:  Curr Med Res Opin       Date:  2009-02       Impact factor: 2.580

Review 4.  What clinicians need to know about antiviral drugs and viral resistance.

Authors:  R L Hodinka
Journal:  Infect Dis Clin North Am       Date:  1997-12       Impact factor: 5.982
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.